Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ardizzoni

Showing results (111-120 of 156) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancerA Ardizzoni, M Venturini, L Crinò, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patientsC Tibaldi, E Giovannetti, M Tiseo, et al.
British Journal of Cancer|February 1, 1994
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancerA Ardizzoni, M Venturini, M R Sertoli, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 6, 2009
A protein microarray immunoassay for the serological evaluation of the antibody response in vertically transmitted infectionsA Ardizzoni, B Capuccini, M C Baschieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts PanelC Gridelli, A Ardizzoni, T Le Chevalier, et al.
British Journal of Cancer|January 1, 1995
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task ForceA Ardizzoni, G F Addamo, E Baldini, et al.
Oncology|January 1, 1989
Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanomaM R Sertoli, M G Bernengo, A Ardizzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancersF Grossi, M Loprevite, M Chiaramondia, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Annals of the New York Academy of Sciences|November 30, 1993
High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factorM Venturini, L Del Mastro, A Ardizzoni, et al.
Pageof 16

Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancerA Ardizzoni, M Venturini, L Crinò, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patientsC Tibaldi, E Giovannetti, M Tiseo, et al.
British Journal of Cancer|February 1, 1994
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancerA Ardizzoni, M Venturini, M R Sertoli, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 6, 2009
A protein microarray immunoassay for the serological evaluation of the antibody response in vertically transmitted infectionsA Ardizzoni, B Capuccini, M C Baschieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts PanelC Gridelli, A Ardizzoni, T Le Chevalier, et al.
British Journal of Cancer|January 1, 1995
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task ForceA Ardizzoni, G F Addamo, E Baldini, et al.
Oncology|January 1, 1989
Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanomaM R Sertoli, M G Bernengo, A Ardizzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancersF Grossi, M Loprevite, M Chiaramondia, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Annals of the New York Academy of Sciences|November 30, 1993
High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factorM Venturini, L Del Mastro, A Ardizzoni, et al.
Pageof 16